Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East.
Merck Serono Neurodegenerative Diseases executive vice president Roberto Gradnik said that they were committed to provide treatments that meet the individual needs of people living with multiple sclerosis at the various stages of the disease.
"Over the years we have continuously worked on enhancing the product profile of Rebif with new formulations, new injection devices and new clinical data," Gradnik said.
"We are very pleased with these new clinical data as they show that patients in the study with the first clinical signs of multiple sclerosis benefited from treatment with Rebif."
The safety profile of Rebif observed in the Reflex study was similar to that seen in other recent studies with the serum-free formulation of Rebif.